Gencurix can diagnose breast cancer through needle biopsy before surgery

Gencurix presented the research results on GenesWell BCT, a breast cancer prognostic test, in an international journal.

GenesWell BCT is a prognostic test that makes the prognosis of other cancer metastasis and recurrence within 10 years, by analyzing the expression levels of six cancer prognostic genes and three standard genes extracted from the RNA of cancer tissues removed during surgery of breast cancer patients.

The study, led by Kyungpook National University Hospital, compared the accuracy of GenesWell BCT test for tissue samples obtained with a core needle biopsy and post-operative tissue specimens for preoperative diagnosis of breast cancer patients